Histopathological Features of Whipple Pancreaticoduodenectomy in Sudan: A Single-center Experience
DOI:
https://doi.org/10.52981/sjms.v17i1.2596Keywords:
periampullary tumors, Whipple pancreaticoduodenectomy, resection, histological features, SudanAbstract
Background: Periampullary tumors (PATs) are rare and Whipple pancreaticoduodenectomy is the commonest surgical approach for its management. The aim of this
study was to analyze the histopathological features of Whipple-resected periampullary
tumors in Sudanese patients.
Methods: This retrospective descriptive study included 62 cases of Whipple resection
seen in a center in Khartoum, Sudan from January 2016 to June 2021. The specimens
were assessed for nine features of the tumor: site of the tumor (whether within
the periampullary region), size of the tumor, histological type of the tumor, grade,
perineural invasion, lymph vascular invasion, surgical margin status, lymph node
metastasis status, and the pathological stage (pTNM).
Results: In total, 62 cases, 40 (64.5%) males and 22 (35.5%) females, were included.
Age ranged from 20 to 90 years with a mean age of 56.08 years (±12.98 SD). Of the
62 cases, 58 were malignant (93.5%), while 4 cases were benign (6.5%). The pancreas
was the commonest site for malignant tumors (53.4%), followed by the ampulla (24.1%),
duodenum (15.5%), and distal common bile duct tumors (DCBD) (7%). The maximum
tumor size was 8 cm, and the number of lymph nodes resected ranged from 3 to
33. Pancreatic ductal adenocarcinomas (PDACs) showed the highest percentage of
perineural (62.1%) and lymphovascular (55.2%) invasions, and a positive margin was
seen in four cases. The most common tumor stage was pT3pN1pMx.
Conclusion: PATs in the Sudanese population showed histological diversity regarding
subtyping, grading, and staging. Further studies involving molecular prognostic
features will support improving patient management.
References
are there differences? Surgical Clinics of North America, vol. 81, no. 3, pp. 543–555.
[2] Dhakhwa, R. and Kafle, N. (2016). Histopathologic analysis of pancreaticoduodenectomy specimen. Journal of Nepal Medical Association, vol. 55, no. 204, pp. 79–85.
.
[3] Foroughi, F., Mohsenifar, Z., Ahmadvand, A. R., et al. (2012). Pathologic findings
of Whipple pancreaticoduodenectomy: a 5-year review on 51 cases at Taleghani
general hospital. Gastroenterology and Hepatology from Bed to Bench, vol. 5, no.
4, pp. 179–182.
[4] Are, C., Dhir, M., and Ravipati, L. (2011). History of pancreaticoduodenectomy: early
misconceptions, initial milestones and the pioneers. HPB: The Ofcial Journal of the
International Hepato Pancreato Biliary Association, vol. 13, no. 6, pp. 377–384.
[5] Yeo, C. J., Cameron, J. L., Sohn, T. A., et al. (1997). Six hundred fifty consecutive
pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes.
Annals of Surgery, vol. 226, no. 3, p. 248.
[6] Fernández-del Castillo, C., Morales-Oyarvide, V., McGrath, D., et al. (2012). Evolution
of the Whipple procedure at the Massachusetts General Hospital. Surgery, vol. 152,
no. 3, pp. S56–S63.
[7] Luchini, C., Capelli, P., and Scarpa, A. (2016). Pancreatic ductal adenocarcinoma and
its variants. Surgical Pathology Clinics, vol. 9, no. 4, pp. 547–560.
[8] Collisson, E. A., Sadanandam, A., Olson, P., et al. (2011). Subtypes of pancreatic ductal
adenocarcinoma and their differing responses to therapy. Nature Medicine, vol. 17,
no. 4, pp. 500–503.
[9] McGuigan, A., Kelly, P., Turkington, R. C., et al. (2018). Pancreatic cancer: a review
of clinical diagnosis, epidemiology, treatment and outcomes. World Journal of
Gastroenterology, vol. 24, no. 43, p. 4846.
[10] Ehehalt, F., Saeger, H. D., Schmidt, C. M., et al. (2009). Neuroendocrine tumors of
the pancreas. The Oncologist, vol. 14, no. 5, pp. 456–467.
[11] Morris-Stiff, G., Alabraba, E., Tan, Y. M., et al. (2009). Assessment of survival
advantage in ampullary carcinoma in relation to tumour biology and morphology.
European Journal of Surgical Oncology, vol. 35, no. 7, pp. 746–750.
[12] Sommerville, C. A., Limongelli, P., Pai, M., et al. (2009). Survival analysis after
pancreatic resection for ampullary and pancreatic head carcinoma: an analysis of
clinicopathological factors. Journal of Surgical Oncology, vol. 100, no. 8, pp. 651–
656.
[13] Westgaard, A., Pomianowska, E., Clausen, O. P., et al. (2013). Intestinal-type and
pancreatobiliary-type adenocarcinomas: how does ampullary carcinoma differ from
other periampullary malignancies? Annals of Surgical Oncology, vol. 20, no. 2, pp.
430–439.
[14] Reid, M. D., Balci, S., Ohike, N., et al. (2016). Ampullary carcinoma is often of mixed
or hybrid histologic type: an analysis of reproducibility and clinical relevance of classification as pancreatobiliary versus intestinal in 232 cases. Modern Pathology,
vol. 29, no. 12, pp. 1575–1585.
[15] Zimmermann, C., Wolk, S., Aust, D. E., et al. (2019). The pathohistological subtype
strongly predicts survival in patients with ampullary carcinoma. Scientific Reports,
vol. 9, no. 1, pp. 1–8.
[16] Kim, W. S., Choi, D. W., Choi, S. H., et al. (2012). Clinical significance of pathologic
subtype in curatively resected ampulla of vater cancer. Journal of Surgical Oncology,
vol. 105, no. 3, pp. 266–272.
[17] Morini, S., Perrone, G., Borzomati, D., et al. (2013). Carcinoma of the ampulla
of Vater: morphological and immunophenotypical classification predicts overall
survival. Pancreas, vol. 42, no. 1, pp. 60–66.
[18] Onkendi, E. O., Boostrom, S. Y., Sarr, M. G., et al. (2012). 15-year experience with
surgical treatment of duodenal carcinoma: a comparison of periampullary and extraampullary duodenal carcinomas. Journal of Gastrointestinal Surgery, vol. 16, no. 4,
pp. 682–691.
[19] Buchbjerg, T., Fristrup, C., and Mortensen, M. B. (2015). The incidence and prognosis
of true duodenal carcinomas. Surgical Oncology, vol. 24, no. 2, pp. 110–116.
[20] Gonzalez, R. S., Bagci, P., Basturk, O., et al. (2016). Intrapancreatic distal common bile
duct carcinoma: analysis, staging considerations, and comparison with pancreatic
ductal and ampullary adenocarcinomas. Modern Pathology, vol. 29, no. 11, pp. 1358–
1369.
[21] Yoshida, T., Matsumoto, T., Sasaki, A., et al. (2002). Prognostic factors after
pancreatoduodenectomy with extended lymphadenectomy for distal bile duct
cancer. Archives of Surgery, vol. 137, no. 1, pp. 69–73.
[22] O’Connell, J. B., Maggard, M. A., Manunga, J., et al. (2008). Survival after resection
of ampullary carcinoma: a national population-based study. Annals of Surgical
Oncology, vol. 15, no. 7, pp. 1820–1827.
[23] Klein, F., Jacob, D., Bahra, M., et al. (2014). Prognostic factors for long-term survival in
patients with ampullary carcinoma: the results of a 15-year observation period after
pancreaticoduodenectomy. HPB Surgery, vol. 2014, article 970234.
[24] Adsay, N. V., Basturk, O., Saka, B., et al. (2014). Whipple made simple for surgical
pathologists: orientation, dissection, and sampling of pancreaticoduodenectomy
specimens for a more practical and accurate evaluation of pancreatic, distal common
bile duct, and ampullary tumors. The American Journal of Surgical Pathology, vol.
38, no. 4, p. 480.
[25] Campbell, F., Cairns, A., Duthie, F, et al. (2019). Dataset for histopathological
reporting of carcinomas of the pancreas, ampulla of Vater and
common bile duct (Document No. G091). London: The Royal College
of Pathologists. https://www.rcpath.org/uploads/assets/34910231-c106-4629-
a2de9e9ae6f87ac1/G091-Dataset-for-histopathological-reporting-of-carcinomasof-the-pancreas-ampulla-of-Vater-and-common-bile-duct.pdf
[26] del Carmen Gómez-Mateo, M., Sabater-Ortí, L., and Ferrández-Izquierdo, A.
(2014). Pathology handling of pancreatoduodenectomy specimens: approaches and
controversies. World Journal of Gastrointestinal Oncology, vol. 6, no. 9, p. 351.
[27] Poultsides, G. A., Huang, L. C., Cameron, J. L., et al. (2012). Duodenal
adenocarcinoma: clinicopathologic analysis and implications for treatment. Annals
of Surgical Oncology, vol. 19, no. 6, pp. 1928–1935.
[28] Shiba, S., Morizane, C., Hiraoka, N., et al. (2016). Pancreatic neuroendocrine tumors:
a single-center 20-year experience with 100 patients. Pancreatology, vol. 16, no. 1,
pp. 99–105.